NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I'll continue talking to myself.

Anyway, here is more reason to consider, POSSIBLY, why Europe's NICE dates might need to be pushed out. In addition to manufacturing readiness (which NWBO is only now developing in Europe for commercial levels), price is decided fairly unilaterally by NICE, by increase in longevity, and that would require NWBO to run out their results further in Europe.

More from NWBIO 10K

Reimbursement agencies in Europe can be even more conservative than CMS in the U.S.A number of cancer drugs which have been approved for reimbursement in the U.S. have not been approved for reimbursement in certain European countries, and/or the level of reimbursement approved in Europe is lower than in the U.S....

....In markets outside the U.S., the prices of medical products are subject to direct price controls and/or to reimbursement with varying price control mechanisms, as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the U.S. Some jurisdictions operate positive and/or negative list systems under which products may only be marketed once a reimbursement price has been agreed. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenues and profits.